Portfolio of Immune Checkpoint Inhibitor Stocks
Here are 4 companies that offer immune checkpoint inhibitor cancer treatments:
- AstraZeneca (AZN) - durvalumab Imfinzi
- Bristol-Myers Squibb (BMY) - nivolumab Opdivo and ipilimumab Yervoy
- Merck (MRK) - pembrolizumab Keytruda
- Roche Holding (RHHBY) - atezolizumab TECENTRIQ
| 4 Checkpoint Inhibitor Stocks | ||
|---|---|---|
Name | Symbol | Recent Prices |
| AstraZeneca | AZN | |
| Bristol-Myers Squibb | BMY | |
| Merck | MRK | |
| Roche Holding AG | RHHBY | |
| Sparkline weekly price charts based on Alpha Vantage data. | ||
| 4 Checkpoint Inhibitor Stocks | ||
|---|---|---|
Name | Symbol | Last Close |
| AstraZeneca | AZN | $55.55 |
| Bristol-Myers Squibb | BMY | $70.53 |
| Merck | MRK | $87.55 |
| Roche Holding AG | RHHBY | $40.47 |
Portfolio Values
To inspect the performance of the Checkpoint Inhibitor Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Alpha Vantage.The 3 stocks included in the portfolio computations are: AZN, BMY and MRK. The current value of the portfolio assumes that $3,333.33 was invested in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. RHHBY was excluded from the portfolio computations because of insufficient price data.The current value of the $10,000 investment is $17,149. The percent return is 71.49%. The annualized return is 11.39%.
| 3 Checkpoint Inhibitor Stocks Returns | ||
|---|---|---|
Name | Symbol | Monthly Returns & Details |
| AstraZeneca | AZN | 87.21% |
| Bristol-Myers Squibb | BMY | 32.33% |
| Merck | MRK | 94.94% |
Portfolio Value Chart for Last 100 Daily Closes
Related Portfolios
Portfolio of Big Pharma and Biotech Cancer Immunotherapy Stocks